KOSDAQElectrical Equipment419540

Bistos

₩3,290▲ 0.61%2026-11-18 close
Market Cap
₩19.6B
Turnover
₩72,651,753
Volume
20K
Shares out.
6M
PER
—
PBR
1.2×
EPS
-₩279
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Bistos: Losses Persist as Listing Test Looms

Bistos has posted operating losses in each of the last five quarters through the third quarter of 2026, and its market capitalization has stayed below KRW 20 billion for 25 consecutive trading days, raising the prospect of a Korea Exchange administrative-issue designation.

  1. 1

    Operating profit turned into an operating loss of KRW 1.1 billion in 2025, and revenue has declined for three straight years from 2023 through 2025.

  2. 2

    Third-quarter 2026 revenue of KRW 3.63 billion fell 15.8% year on year, and the KRW 1.13 billion net loss attributable to controlling shareholders was the largest of the last five quarters.

  3. 3

    The company exports to 96 countries with overseas sales reported at about 80% of revenue, and it is expanding its Yongin plant.

  4. 4

    Market capitalization had been below KRW 20 billion for 25 trading days as of November 17, 2026, and five more trading days below that level would make a designation possible.

  5. 5

    Together with its largest shareholder CU Medical Systems, the company has bought back shares and approved articles changes that enlarge its capacity for third-party share issues and convertible and warrant bonds.

02

Business structure

Bistos (419540) is a maker of biosignal diagnostic and therapeutic medical devices founded in 2001, and it listed on KOSDAQ in October 2022.

Its core products are biosignal diagnostic and monitoring devices such as fetal monitors and patient monitors, and the line has been extended to maternal and neonatal care products and breast pumps.

The company holds patents on new products including an ADHD treatment device and an incubator, and it is developing brain-related electrical stimulation devices and a wearable healthcare baby monitor as new business areas.

The sales structure is overwhelmingly overseas: it reportedly exports to 96 countries, with overseas sales at about 80% of revenue.

Its largest shareholder is CU Medical Systems, a maker of automated external defibrillators (AED), and the combined stake of the largest shareholder and related parties was 34.20% as of June 2026.

In November 2026 the two companies jointly exhibited at MEDICA 2026 in Düsseldorf, presenting products from AEDs to maternal and neonatal care and patient monitoring. The company is also pursuing plans to offer its products through overseas distributors that already carry CU Medical Systems products.

For 2025, the company cited intensifying competition in its main sales markets and a higher exchange rate as the main reasons for lower sales and operating profit.

The export-led structure provides a base for overseas expansion, but it also leaves the business directly exposed to exchange rates and competitive pressure.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.3B-₩500M−10.7%
2025Q4₩4.6B-₩65,843,881−1.4%
2026Q1₩3B-₩400M−13.2%
2026Q2₩4.2B-₩900M−20.4%
2026Q3₩3.6B-₩600M−16.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩24B₩900M-₩4.5B3.8%−28.3%28.7%
2023₩21.3B₩300M₩800M1.3%4.3%16.1%
2024₩20.3B₩300M₩800M1.5%4.4%10.4%
2025₩17.1B-₩1.1B-₩700M−6.4%−3.9%15.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue fell from KRW 24 billion in 2022 to KRW 21.3 billion in 2023 (down 11.1% year on year), KRW 20.3 billion in 2024 (down 4.9%) and KRW 17.1 billion in 2025 (down 15.6%), a decline of three straight years from 2023 through 2025. Of the 2022 to 2025 period, 2022 was the year with the largest revenue.

Operating profit went from KRW 913 million in 2022 to KRW 284 million in 2023 (down 68.9%), recovered slightly to KRW 311 million in 2024 (up 9.7%), and turned into an operating loss of KRW 1.1 billion in 2025. The operating margin slid from 3.8% in 2022 and 1.3% in 2023 and 1.5% in 2024 to -6.4% in 2025.

Profit attributable to controlling shareholders swung from a loss of KRW 4.5 billion in 2022 to a profit of KRW 806 million in 2023, rose to KRW 848 million in 2024 (up 5.1%), and returned to a loss of KRW 699 million in 2025.

In 2022, operating profit was positive at KRW 913 million while the loss attributable to controlling shareholders reached KRW 4.5 billion, which suggests that items below the operating line weighed heavily.

The company attributed the 2025 deterioration to intensified competition, lower sales and operating profit from a higher exchange rate, and higher selling and administrative expenses. Operating cash flow moved from KRW 2.44 billion in 2024 to an outflow of KRW 2.17 billion in 2025.

Quarterly, the third quarter of 2025 showed revenue of KRW 4.31 billion, an operating loss of KRW 459 million and a net loss attributable to controlling shareholders of KRW 477 million.

In the fourth quarter of 2025 revenue rose 6.8% quarter on quarter to KRW 4.6 billion, the operating loss narrowed to KRW 65.84 million, and profit attributable to controlling shareholders was KRW 309 million.

The first quarter of 2026 revenue fell 35.4% quarter on quarter to KRW 2.97 billion, with an operating loss of KRW 391 million. In the second quarter of 2026 revenue rose 41.2% to KRW 4.2 billion, yet the operating loss widened to KRW 856 million.

The company said the first-half 2026 swing reflected production schedule changes during facility expansion works at its Yongin and Wonju plants, with about KRW 3 billion of sales shifted into the third quarter and higher initial costs and depreciation.

Third-quarter 2026 revenue was KRW 3.63 billion, down 15.8% year on year, with an operating loss of KRW 597 million and a net loss attributable to controlling shareholders of KRW 1.13 billion.

The net loss attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totals KRW 1.66 billion.

05

Industry analysis

Bistos operates in biosignal devices for maternal and neonatal care and patient monitoring, which places it directly in export competition within global medical devices.

The company cited intensifying competition in its main sales markets as a factor behind the 2025 decline, which in practice points to tougher pricing and channel competition.

MEDICA 2026, which opened in Düsseldorf on November 16, 2026, has been described as the world's largest medical device trade fair, and Bistos held one-to-one buyer meetings there. Because overseas sales account for about 80% of revenue, exchange-rate moves feed quickly into sales and profit.

The company's citation of a higher exchange rate as a factor in the 2025 decline fits the same pattern. Evidence on where the industry sits in its cycle is limited, but the current phase combines capacity expansion with a push into overseas distribution.

Against peers, Bistos is small in revenue terms, and the company presents its shared distribution channel with the AED maker CU Medical Systems as a differentiator. Whether that channel sharing has translated into higher orders is not yet clearly visible in the figures the company has disclosed.

06

Outlook

In August 2026 the company said that once facility works are complete, production efficiency should improve and sales and profitability should recover gradually from the second half of 2026.

Third-quarter 2026 revenue, however, fell 15.8% year on year with an operating loss of KRW 597 million, so a gap remains between the recovery the company describes and reported results. Reports in November 2026 describe the Yongin plant expansion as ongoing, aimed at handling a rise in overseas orders steadily.

At MEDICA 2026 the company exhibited jointly with CU Medical Systems and is pursuing plans to offer its products through that partner's overseas distributors.

Among new businesses, it is developing brain-related electrical stimulation devices and a wearable healthcare baby monitor, and the timing of any sales contribution from these products is difficult to gauge from the material currently available.

On capital, an extraordinary shareholders meeting in October 2026 considered articles changes that would raise the third-party allotment limit from 20% to 50% of issued shares and lift the limits for convertible and warrant bonds from KRW 10 billion to KRW 100 billion each, and reports said the changes were approved.

In June 2026 the company entered a share buyback trust agreement worth KRW 2 billion and added KRW 1 billion in August. Trading in common shares was suspended from April 30, 2026 for a share consolidation procedure.

The next checkpoints are the annual results in the 2026 business report and whether the Yongin expansion shows up in revenue in the first quarter of 2027.

07

Valuation

PER
—
PBR
1.2×
ROE
-9.6%
EPS
-₩279
BPS
₩2,852
Dividend per share
₩0

Because the last four quarters show a net loss attributable to controlling shareholders, the price-to-earnings ratio cannot be calculated. Unlike 2023 and 2024, when profit attributable to controlling shareholders was positive, there is little earnings-based multiple history to compare against.

The price-to-book ratio sits slightly above 1 times, which means a modest premium over net asset value rather than a large one. While losses continue, it is hard to judge whether asset value is supporting the share price, and the comparison basis will shift with the pace of recovery.

The dividend yield is close to zero and below the industry average. Market capitalization remains below the KRW 20 billion listing threshold, and the company has responded with share buybacks and a larger capacity for share issues.

Since losses have persisted since 2025, earnings-based multiples will carry more meaning once the company returns to profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Overseas channels and Yongin expansion

Exports to 96 countries and overseas sales at about 80% of revenue give the company an established channel base. The Yongin expansion is meant to add capacity for a rise in overseas orders. The company said sales and profitability should recover gradually from the second half of 2026 once facility works finish.

Distribution tie-up with CU Medical Systems

The company ran a joint booth with its largest shareholder CU Medical Systems at MEDICA 2026 in November 2026. Whether supply items actually expand through the overseas distributor channel is the next point to check. The idea is to share buyer networks to open new sales routes.

Capital capacity and buybacks

At the end of 2025 total liabilities were KRW 2.8 billion against total equity of KRW 17.9 billion, with a debt-to-equity ratio of 15.6%. The company entered a KRW 2 billion buyback trust in June 2026 and added KRW 1 billion in August.

An October 2026 extraordinary shareholders meeting took up articles changes that widen third-party allotment and bond limits.

09

Bear factors

Continuing revenue decline

Revenue fell for three straight years from 2023 through 2025, and it dropped 15.6% in 2025. The first quarter of 2026 recorded KRW 2.97 billion, the lowest of the last five quarters. Third-quarter 2026 revenue of KRW 3.63 billion was still down 15.8% year on year, so the decline has continued.

Five straight quarters of operating losses

The company has booked operating losses in each of the five quarters from the third quarter of 2025 through the third quarter of 2026. In the second quarter of 2026, the operating loss widened to KRW 856 million even though revenue rose.

The net loss attributable to controlling shareholders over the last four quarters totals KRW 1.66 billion, and the KRW 1.13 billion loss in the third quarter of 2026 was the largest of the last five quarters.

Listing pressure and dilution risk

Market capitalization has been below KRW 20 billion for 25 trading days, and the Korea Exchange has warned that a designation could follow. Reports say the threshold will rise to KRW 30 billion in 2027. The larger third-party allotment and bond limits could dilute existing shareholders if they are used.

10

Risk factors

Listing maintenance threshold

If market capitalization stays below KRW 20 billion for five more trading days, an administrative-issue designation becomes possible. Such a designation could weigh on funding and credibility. The company says it will keep buying back shares and take other steps to keep market capitalization above the threshold.

Exchange rates and overseas dependence

Overseas sales at about 80% of revenue make the company's results sensitive to exchange rates. The company cited a higher exchange rate as a factor behind the 2025 decline. Because sales depend on overseas distributors and partners, changes in those relationships could also disrupt supply.

Capex execution and new businesses

In the first half of 2026, facility works shifted about KRW 3 billion of sales into the third quarter. If production schedules slip again, revenue recognition could keep moving between quarters.

The new wearable healthcare and brain-related stimulation businesses are still in development, and their commercial results are not yet visible in reported figures.

11

What to watch next

  1. November 18–24, 2026 (five trading days)

    The question is whether market capitalization stays below KRW 20 billion for five more trading days. If it does, the stock could move into the administrative-issue designation process.

  2. After November 19, 2026

    After MEDICA 2026 closes, the checkpoint is whether buyer talks turn into supply items through CU Medical Systems' overseas distributors.

  3. End of March 2027 (business report deadline)

    The 2026 annual revenue, operating profit and fourth-quarter results will enter the disclosed record. They show whether the loss trend since 2025 continues.

  4. Before May 15, 2027 (first-quarter 2027 quarterly report)

    This is where to check whether the Yongin expansion first shows up in quarterly sales and whether the operating loss narrows.

  5. In 2027, when the threshold rises

    When the listing threshold rises to KRW 30 billion, the checkpoint is whether the larger issuance limits lead to actual fundraising.

12

Overall view

Bistos's revenue declined from KRW 24 billion in 2022 to KRW 17.1 billion in 2025, and the company swung to an operating loss of KRW 1.1 billion in 2025.

Operating losses have continued across five straight quarters through the third quarter of 2026, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 1.66 billion.

Strengths include an export network reaching 96 countries with overseas sales at about 80% of revenue, the Yongin plant expansion, and the distribution tie-up with CU Medical Systems. Weaknesses include three straight years of revenue decline, continuing losses, and dependence on exchange rates and overseas channels.

Market capitalization has been below KRW 20 billion for 25 trading days, which has raised the possibility of an administrative-issue designation, and the company is responding with buybacks and articles changes.

The next checkpoints are the annual results in the 2026 business report and whether the Yongin expansion shows up in revenue in the first quarter of 2027. This report is for information only and contains no buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. bistos.co.kr
  2. sedaily.com
  3. comp.fnguide.com
  4. view.asiae.co.kr
  5. greened.kr
  6. news.nate.com
  7. sentv.co.kr
  8. alphasquare.co.kr
  9. stockvery.com
  10. dealsite.co.kr
  11. topstarnews.net
  12. google.com
  13. topstarnews.net
  14. news.nate.com
  15. m.news.nate.com
  16. news.nate.com
  17. m.news.nate.com
  18. g-enews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis